All In Biotech

Drug Trial Radar · NCT06144970

Study to Determine the Safety and Tolerability of TG-C in Subjects With Back Pain Due to Degenerative Disc Disease

A Phase I, Double-blind, Randomized, Sham-controlled, Dose-response, Study Evaluating the Safety and Tolerability of TG-C in Subjects With Chronic Discogenic Lumbar Back Pain Due to Degenerative Disc Disease at 6 and 12 Months

Last checked: Nov 20, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Jan 19, 2027

Primary completion

Jul 28, 2028

Study completion Jul 28, 2029

Sponsor

Lead sponsor
Kolon TissueGene, Inc.Industry
Sponsor type
Industry
First posted
Nov 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 22 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to evaluate the safety and tolerability of TG-C in subjects with chronic discogenic lumbar back pain due to degenerative disc disease. Participants will be administered a single intradiscal injection or subcutaneous injection for sham and followed up with in-clinic visits and telephone calls for 24 months.

Conditions

  • Degenerative Disc Disease

Interventions

  • TG-C High DoseBiological

    High Dose - 1 mL of the combined TG-C cells

  • TG-C Mid DoseBiological

    Middle Dose - A volume of 2 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected

  • TG-C Low DoseBiological

    Low Dose - A volume of 9 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected

  • Sham ControlBiological

    Single subcutaneous injection of normal saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse eventsTime frame: 6 and 12 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.